Insights
Search Results
News Articles
6.05.26
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 List of Next-Generation Lawyers
Ten Wilson Sonsini attorneys have been recognized in the 2026 edition of Lawdragon 500 X – The Next Generation. Individuals listed in the guide are “the future of the law” and are recognized for their accomplishments in their career thus far.
Client Highlights
3.27.26
Wilson Sonsini Advises OnKure Therapeutics on $150 Million Private Placement
On March 27, 2026, OnKure Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel precision medicines, announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million. Wilson Sonsini Goodrich & Rosati advised OnKure on the transaction.
Client Highlights
3.17.26
Firm Advises R1 Therapeutics on $77.5 Million Series A Financing
On March 17, 2026, R1 Therapeutics, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc., with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. Wilson Sonsini Goodrich & Rosati advised R1 on the financing.
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Case Studies
12.11.25
How Wilson Sonsini Helped Ensure Light Horse Therapeutics’ Impressive Debut
Light Horse Therapeutics is pioneering new technologies to tackle the root causes of disabling and life-threatening diseases. Using precision gene editing applied to small-molecule drug discovery, its innovative approach is currently targeting historically challenging cancers, with plans to apply the technology to other therapeutic areas in the future.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
11.26.25
Wilson Sonsini Advises Dayra Therapeutics on Strategic Collaboration with Biogen Inc.
On November 24, 2025, Dayra Therapeutics, a start-up focused on developing oral macrocyclic peptide therapeutics to treat a range of human diseases, announced a research collaboration with Biogen Inc.
Client Highlights
7.25.25
Wilson Sonsini Advises Cooler Heads on $11 Million Series A
On July 22, 2025, Cooler Heads announced that it has closed an oversubscribed $11 million Series A funding round to expand the manufacturing and rollout of Amma™, the only FDA-cleared Portable Scalp Cooling System. The financing was led by Mutual Capital Partners, a Cleveland healthtech-focused venture capital fund, with participation from SHD Partners, Crescent Ridge VC, Cal Innovation Fund, NuFund, Robin Hood Ventures, Golden Seeds, HIP VC, and an unnamed strategic investor. Wilson Sonsini Goodrich & Rosati advised Cooler Heads on the transaction.
The Amma™ system helps chemotherapy patients keep their hair and preserve their privacy, eliminating the disfiguring hair loss that has long been an accepted side effect of chemotherapy. The proceeds from the Series A financing will be used to increase manufacturing capacity, expand the commercial team, and develop the next generation of the product.
The Wilson Sonsini team that advised Cooler Heads on the transaction included Karen Deschaine, Phil McGill, Dani Glazer Signaigo, and Matt Fleming.
For more information, please see the Cooler Heads news release.
The Amma™ system helps chemotherapy patients keep their hair and preserve their privacy, eliminating the disfiguring hair loss that has long been an accepted side effect of chemotherapy. The proceeds from the Series A financing will be used to increase manufacturing capacity, expand the commercial team, and develop the next generation of the product.
The Wilson Sonsini team that advised Cooler Heads on the transaction included Karen Deschaine, Phil McGill, Dani Glazer Signaigo, and Matt Fleming.
For more information, please see the Cooler Heads news release.
News Articles
7.17.25
Phil McGill Honored Among SDBJ’s 40 Next Top Business Leaders Under 40
On July 14, 2025, Corporate partner Phil McGill was named among San Diego Business Journal’s “40 Next Top Business Leaders Under 40,” which is a special supplement recognizing young professionals for their achievements and community involvement in the region.
News Articles
7.11.25
Lawdragon Names 12 Wilson Sonsini Lawyers to Its 2025 List of Next-Generation Lawyers
Twelve Wilson Sonsini attorneys have been recognized in the 2025 Lawdragon 500 X – The Next Generation, the third edition of the guide. Individuals listed in the guide traditionally have “proven themselves early in private practice, accruing credentials, deals, and cases early and often,” with the majority of lawyers having been in practice between seven and fifteen years.
Client Highlights
2.20.25
Wilson Sonsini Advises Versant Ventures and OrbiMed on Helicore Biopharma's $65 Million Series A
On January 28, 2025, Helicore Biopharma, a biopharmaceutical company focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions, emerged from stealth with $65 million in Series A financing. The round was co-led by founding investor Versant Ventures and by OrbiMed, with participation from Longitude Capital and Wellington Management. Wilson Sonsini Goodrich & Rosati advised Versant Ventures and OrbiMed on the transaction.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on $62 Million Series A
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its debut $62 million Series A financing. The financing, announced on January 9, 2025, was led by founding investor Versant Ventures and included Mubadala Capital as well as three strategic investors: Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie. Light Horse is the latest company started by Versant’s Inception Discovery Engine, and its scientific co-founders are Brian Liau, Ph.D., Ben Cravatt, Ph.D., and Nathanael Gray, Ph.D.